Skip to content

Research of Traditional Chinese Medical syndromes and their influencing factors on actue Suilao allogeneic hematopoietic stem cell transplantation and Chinese herbal effect

Research of Traditional Chinese Medical syndromes and their influencing factors on actue Suilao allogeneic hematopoietic stem cell transplantation and Chinese herbal effect

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16008030
Enrollment
Unknown
Registered
2016-03-01
Start date
2016-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe aplastic anemia(SAA)

Interventions

controlled arm:allogeneic hematopoietic stem cell transplantation
treatment group:allogeneic hematopoietic stem cell transplantation+Chinese Herbal granules

Sponsors

Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnosis of severe aplastic anemia(SAA-I); 2. Not enrolled in other clinical trials; 3. Patients from 6 years old to 50 years old; 4. Sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pancytopenia attributing to other disorders,such as actue arrest of hemopoiesis,myelofibrosis and ect; 2. Severe comorbidities associated with cardio-cerebrovascular,liver and kidney or psychosis; 3. Associate with severe arrhythmia,such as rapid atrial fibrillation,atrial flutter,paroxysmal ventricular tachycardia and ect; 4. Associate with active peptic ulcer or other hemorrhagic disease; 5. Women in pregnancy, preparation for pregnancy or breast feeding period; 6. Allergic constitution; 7. Nearly three months have enrolled in other clinical trials or be enrolling in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medical efficacy;Traditional Chinese Medical Index of pathological basis;

Secondary

MeasureTime frame
index of hematopoietic recovery ;implanted situation;safety;

Countries

China

Contacts

Public ContactWu Dijiong
wdj850@163.com+8613989463963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026